Editorial Policies

Focus and Scope

Until now, no journal has put the whole spectrum of neurodegeneration and regeneration from basic clinical research to case studies between its covers. With the introduction of the Journal of Neurodegeneration and Regeneration that now happens as the nation's top experts in the field bring to the medical community a long awaited exploration of the basic and clinical new and ongoing research being conducted in this critical field, research that will lead to better diagnosis, more effective treatments and ultimately, perhaps, cures.

Although great progress has been made in recent years toward understanding neurodegenerative diseases like Alzheimer's, Parkinson's, multiple sclerosis, ALS and others, few effective treatments and no cures are currently available. So the element of urgency is here. The numbers speak for themselves. In the United States alone, almost five million suffer from Alzheimer's disease; one million from Parkinson's disease; 400,000 from multiple sclerosis; and 30,000 from ALS. Worldwide, these four diseases account for more than 20 million patients.

Further, it is generally accepted that things are going to get worse before they get better. Aging greatly increases the risk of neurodegenerative disease and the average age of Americans and the populations of many other countries is increasing. Today, over 37 million Americans alone are over the age of 65. Within the next 30 years this number is likely to double, putting more and more people at increased risk of neurodegenerative diseases.

The Journal of Neurodegeneration and Regeneration is guided by an international editorial review board of the foremost experts in the field under the leadership of co-Editors-in-Chief Dr. Philippe Taupin, PhD and Dr. Cathy M. Helgason, MD.

Its primary focus will be on recent developments in understanding the molecular mechanisms of neurodegenreration, neuroprotection and neuroregeneration including experimental approaches and their relevance in treating neurodegenerative disorders. Readers now have access to in-depth coverage of such things as:

  • Recent developments in understanding the molecular mechanisms of neurodegeneration and neuroprotection
  • The role of acetylcholinesterase in neurodegenerative diseases
  • Understanding the aetiology of major neurodegenerative diseases and identifying ways of early detection
  • The pathophysiological function of JNK
  • The role of extracellular proteolysis by metalloproteases such as ADAMB in neuroprotection

 

Section Policies

Articles

Checked Open Submissions Checked Indexed Checked Peer Reviewed
 

Peer Review Process

We enforce a rigorous double blinded peer-review process on all submissions to the journal.

 

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.